

The **first and only DHE autoinjector** for the acute treatment of migraine with or without aura and cluster headache in adults^{1,2}

How to prescribe Brekiya autoinjector



INDICATIONS

Brekiya is an ergotamine derivative indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Limitations of Use:

Brekiya is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura.

IMPORTANT SAFETY INFORMATION

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS

Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of Brekiya with strong CYP3A4 inhibitors is contraindicated.

Please see the Brekiya Full Prescribing Information, including Boxed Warning and Medication Guide in the pocket.

Your patients can get started in just 3 simple steps

Step 1

Send their prescription to one of the following specialty pharmacies:



E-prescribe:

Sterling Specialty Pharmacy
1312 Northland Drive, Suite 500
Mendota Heights, MN 55120

Phone number: 888-618-4126

Fax number: 866-588-0371



E-prescribe:

Walgreens Specialty
Pharmacy

Phone number: 888-282-5166

Fax number: 888-570-4700

To minimize callbacks, be sure to include the ICD-10-CM code and patient cell phone number on the prescription. Standard data rates may apply.

Coding for reimbursement³

ICD-10-CM CODE	ICD-10-CM CODE DESCRIPTION
G43.0	Migraine without aura
G43.1	Migraine with aura
G43.9	Migraine, unspecified
G44.001	Cluster headache syndrome, unspecified, intractable
G44.009	Cluster headache syndrome, unspecified, not intractable
G44.011	Episodic cluster headache, intractable
G44.019	Episodic cluster headache, not intractable

Step 2

The specialty pharmacies will initiate the insurance claim.

The specialty pharmacy will conduct a benefits investigation to confirm your patient's insurance coverage. Their staff is already familiar with the correct billing and coding information to assist with the initial claim, and additional paperwork including:

- ✓ Prior Authorizations
- ✓ Letters of Medical Necessity or Exception

The specialty pharmacies may reach out to your patient for additional information, if needed.

Step 3

The specialty pharmacies will mail Brekiya autoinjector directly to your patient's preferred location.

Brekiya autoinjector is packaged in a carton containing 4 autoinjectors. Prescribe in multiples of 4.



Copay program

Copay Program

Patients with **commercial insurance may pay as little as \$40** per carton (4 single-dose autoinjectors). The specialty pharmacy will enroll qualified commercially insured patients automatically at prescription dispense, no cards or coupons needed. Restrictions apply. Please see terms, conditions, and eligibility criteria at Brekiya.com.

INDICATIONS

Brekiya is an ergotamine derivative indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Limitations of Use:

Brekiya is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura.

IMPORTANT SAFETY INFORMATION

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS

Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of Brekiya with strong CYP3A4 inhibitors is contraindicated.

CONTRAINDICATIONS

- Concomitant use of strong CYP3A4 inhibitors
- Ischemic heart disease or coronary artery vasospasm
- Uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment
- Concomitant use of other 5-HT₁ agonists or ergotamine-containing or ergot-type medications within 24 hours
- Hypersensitivity to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in Brekiya.
- Concomitant use with peripheral and central vasoconstrictors

WARNINGS AND PRECAUTIONS

- *Myocardial Ischemia and/or Infarction, Other Cardiac Adverse Reactions, and Fatalities:* In patients with risk factors predictive of coronary artery disease, consider first dose administration under medical supervision with an electrocardiogram.
- *Cerebrovascular Adverse Reactions and Fatalities:* Cerebrovascular hemorrhage, subarachnoid hemorrhage, and stroke have been reported; discontinue Brekiya if suspected.
- *Other Vasospasm Related Adverse Reactions:* Brekiya may cause vasospasm or elevation in blood pressure. Discontinue if signs or symptoms of vasoconstriction develop.
- *Medication Overuse Headache:* Detoxification may be necessary.
- *Preterm Labor:* Advise pregnant women of the risk.
- *Fibrotic Complications:* Pleural and retroperitoneal fibrosis have been reported following prolonged daily use of dihydroergotamine mesylate. Do not exceed the Brekiya dosing guidelines or use for chronic daily administration.

ADVERSE REACTIONS

Serious cardiac events (including fatal) that have been reported with dihydroergotamine mesylate injection use include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation.

DOSAGE AND ADMINISTRATION

- For subcutaneous injection only.
- Recommended dosage is 1 mg administered subcutaneously as a single 1 mL autoinjector.
- Do not exceed 3 mg (3 doses) in a 24-hour period.
- Do not exceed 6 mg (6 doses) in a week.
- Prior to initiation, a cardiovascular evaluation is recommended.

DRUG INTERACTIONS

- *Beta Blockers/Nicotine:* May potentiate/provoke vasoconstriction.
- *Selective Serotonin Reuptake Inhibitors:* Weakness, hyperreflexia, and incoordination may occur with coadministration.

USE IN SPECIFIC POPULATIONS

- Pregnancy: Based on animal data, may cause fetal harm.
- Lactation: Advise not to use during breastfeeding and for 3 days after the last dose.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Global Patient Safety at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the Brekiya Full Prescribing Information, including Boxed Warning and Medication Guide in the pocket.

References: **1.** Brekiya [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2025. **2.** Data on file, Amneal Pharmaceuticals LLC. **3.** Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. Accessed December 8, 2025. <https://www.cms.gov/medicare/coding-billing/icd-10-codes>

Patient assistance programs available for eligible patients prescribed **Brekiya autoinjector**



Head Start Program

To determine eligibility for the Head Start program, your patient **must have**:

1. Previously submitted a prescription through one of the two specialty pharmacies
2. A denied prior authorization with an appeal pending

Eligible patients who meet the criteria above may receive up to 3 Brekiya autoinjector cartons (4 single-dose autoinjectors per carton) at no cost within a consecutive 90-day period until a coverage decision is rendered. Prescriber must **send a new prescription** with ICD-10 code to:

✓ TC Script, LLC
NPI: 1104391770
8275 N. Pima Road, Suite 1
Scottsdale, AZ 85258

✓ Phone: 855-584-6189
✓ Fax: 855-578-1691



Patient Assistance Program

Assists eligible patients who **do not currently have insurance coverage** for Brekiya autoinjector. Eligibility is determined after a complete application is received. Terms and conditions apply including financial eligibility criteria.

SCAN THIS QR CODE OR VISIT [BREKIYAHCP.COM](https://brekiyahcp.com) TO LEARN MORE.



Amneal

Brekiya is a registered trademark of Amneal Pharmaceuticals LLC.
All other trademarks are property of their respective owners.
© 2026 Amneal Pharmaceuticals LLC. All rights reserved.
Printed in the USA. PP-ADP-BRK-US-0006 05/2026